(IHE) U.S. Pharmaceuticals - Overview
ETF Category: Health | Exchange: NYSE (USA) | Market Cap: 922m USD | Total Return: 42.2% in 12m
Avg Turnover: 5.42M
Warnings
No concerns identified
Tailwinds
Idiosyncratic Leader
The iShares U.S. Pharmaceuticals ETF (IHE) tracks an index composed of domestic companies involved in the development, manufacture, and distribution of prescription drugs, over-the-counter medications, and vaccines. Launched in 2006, the fund typically allocates a minimum of 80% of its assets to these index components, while maintaining the flexibility to use derivatives and cash equivalents for the remainder. As a non-diversified fund, it maintains concentrated positions within a specific industrial niche.
The pharmaceutical sector is characterized by high research and development (R&D) costs and a business model heavily dependent on patent protections to secure long-term revenue streams. Unlike broader healthcare providers, these manufacturers face unique regulatory hurdles through the FDA approval process, which dictates product lifecycles and market entry. For a deeper look into how these regulatory cycles impact specific holdings, you may find further insights on ValueRay.
- Medicare price negotiations under Inflation Reduction Act impact drug margins
- FDA approval cycles and R&D pipeline productivity drive valuation
- Patent expirations trigger revenue loss to low-cost generic competition
- Consolidation through M&A activity influences sector capital allocation efficiency
As of June 08, 2026, the stock is trading at USD 92.69 with a total of 104,340 shares traded.
Over the past week, the price has changed by +1.06%,
over one month by +4.53%,
over three months by +5.05% and
over the past year by +42.18%.
U.S. Pharmaceuticals has no consensus analysts rating.